Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2021, with a specific transaction date of December 21, 2021. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific executive transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Price: $43.3600 per ADS
- Transaction Volume: 1,153.319 ADSs
- Transaction Value: Approximately $50,008 (calculated)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of notional ADSs within the GSK Executive Supplemental Savings Plan account by Dr. H. Barron, Chief Scientific Officer and President, R&D.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of a single insider transaction executed on the New York Stock Exchange (XNYS).
Key Facts for Investor Verification
- Verify the total holdings of Dr. H. Barron following this acquisition to assess insider confidence levels.
- Confirm the market price of GSK ADSs on December 21, 2021, to validate the transaction price of $43.36.
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.